Your Partner in Innovative Cancer Care

Together with you – the healthcare professional in practice or training – we’re finding the answers, insights, and treatment options that people with cancer deserve.

How to Refer a Patient

Memorial Sloan Kettering’s Patient Access Service is an easy way for doctors to refer a patient to a Memorial Sloan Kettering specialist. Find helpful phone numbers and other resources.


Our renowned fellowship programs prepare doctors for leadership roles in the care of people with cancer around the world.

Learn more

Clinical Trials

At any one time Memorial Sloan Kettering is running hundreds of clinical trials. Through these studies we can improve care for people with all types of cancer. Browse the MSK clinical trials that are currently enrolling new patients.

Prediction Tools

MSK’s researchers have developed prediction tools known as nomograms. These tests can help people with cancer and doctors make treatment decisions. The tools can be used to predict cancer outcomes. Nomograms also assess an individual’s risk based on the characteristics of their specific disease.

Clinical Updates & Insights

Get the latest updates from MSK doctors. Read about new treatments, clinical trials, and innovations in detecting and treating many cancers.
Pictured: Michael Zelefsky

Clinical Update

Image-Guided RT Reduces Potential Under-Dosing in High-Risk Prostate Cancer

All radiotherapy treatments for prostate cancer should be accompanied by image-guidance of the prostate position to rule out significant setup errors in fractional delivery.

Howard Scher

Clinical Update

Profiling Prostate Tumors for MSI May Inform Better Treatment Selection

Profiling prostate cancer tumors for microsatellite instability (MSI) status with targeted next-generation sequencing can identify patients who may respond better to PD-1/PD-L1 agents.

James Eastham

Clinical Update

Prostatectomy and RT Combination Yields Favorable Outcomes in Advanced Prostate Cancer

Men with advanced prostate cancer treated with radical prostatectomy and adjuvant radiotherapy have a lower risk of cancer-specific death and improved overall survival compared to men treated with radiotherapy plus androgen deprivation therapy.